A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs TRX 818 (Primary)
- Indications Cancer; Leukaemia; Lymphoma; Multiple myeloma; Solid tumours
- Focus Adverse reactions
- Sponsors TaiRx
- 06 Jun 2017 Results (n=28) from NCT02507544 and NCT02703298 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 17 Oct 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
- 23 Sep 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History